Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan QT/QTc Study in Healthy Subjects
NCT02050802Phase 1Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Aug 2011
- Primary completion
- Nov 2011
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of macitentan in pulmonary arterial hypertension (PAH) (8 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Baseline-adjusted placebo-corrected QT interval according to Fridericia's correction at Day 8. Started Aug 2011; status: completed.
02
Drugs
macitentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02050802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02050802.